SeaStar Medical

ICU

Market cap $11.1M

FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients

DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 3rd at 4:00 pm Eastern Standard Time. Interested investors and guests of SeaStar Medical are welcome to attend the conference.

DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer.

Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance Registry New clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollment Strengthened the balance sheet, raising $12.4 million to fund future operations Webcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended September 30, 2025, and provided business updates on key initiatives.

DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.

Data show results consistent with clinical trial experience A high level of safety – no device-related adverse events Strong survival data extending to 90 days

Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power

DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical and its research collaborators at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation will highlight the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Safety data will also be presented.

DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference.

DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the publication of a health economic analysis estimating significant cost savings with the use of the QUELIMMUNE therapy in pediatric patients with Acute Kidney Injury (AKI) in the ICU setting.